EUROAPI SASU (EAPI.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:EAPI - FR0014008VX5 - Common Stock
3.108 EUR
-0.02 (-0.64%)
EAPI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. While EAPI seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, EAPI is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
EAPI had negative earnings in the past year.
In the past year EAPI had a positive cash flow from operations.
EAPI had negative earnings in each of the past 5 years.
EAPI had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -8.62%, EAPI is not doing good in the industry: 69.09% of the companies in the same industry are doing better.
EAPI has a worse Return On Equity (-13.04%) than 67.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.62% | ||
| ROE | -13.04% | ||
| ROIC | N/A |
ROA(3y)-7.13%
ROA(5y)-4.46%
ROE(3y)-11.69%
ROE(5y)-7.3%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EAPI has a Gross Margin of 13.71%. This is in the lower half of the industry: EAPI underperforms 78.18% of its industry peers.
In the last couple of years the Gross Margin of EAPI has grown nicely.
The Profit Margin and Operating Margin are not available for EAPI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 13.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.23%
GM growth 5Y10.12%
2. Health
2.1 Basic Checks
EAPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
EAPI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for EAPI has been increased compared to 5 years ago.
EAPI has a better debt/assets ratio than last year.
2.2 Solvency
EAPI has an Altman-Z score of 1.99. This is not the best score and indicates that EAPI is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.99, EAPI is doing worse than 63.64% of the companies in the same industry.
EAPI has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
EAPI has a better Debt to Equity ratio (0.07) than 85.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.99 |
ROIC/WACCN/A
WACC7.89%
2.3 Liquidity
EAPI has a Current Ratio of 2.53. This indicates that EAPI is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of EAPI (2.53) is better than 81.82% of its industry peers.
EAPI has a Quick Ratio of 2.53. This is a bad value and indicates that EAPI is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.80, EAPI is not doing good in the industry: 61.82% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.53 | ||
| Quick Ratio | 0.8 |
3. Growth
3.1 Past
EAPI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.83%, which is quite impressive.
Looking at the last year, EAPI shows a decrease in Revenue. The Revenue has decreased by -9.11% in the last year.
The Revenue has been growing slightly by 0.07% on average over the past years.
EPS 1Y (TTM)56.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.35%
Revenue 1Y (TTM)-9.11%
Revenue growth 3Y0.98%
Revenue growth 5Y0.07%
Sales Q2Q%-8.07%
3.2 Future
The Earnings Per Share is expected to grow by 24.98% on average over the next years. This is a very strong growth
EAPI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.98% yearly.
EPS Next Y71.33%
EPS Next 2Y43.63%
EPS Next 3Y37.28%
EPS Next 5Y24.98%
Revenue Next Year-2.9%
Revenue Next 2Y-3.71%
Revenue Next 3Y-1.19%
Revenue Next 5Y0.98%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for EAPI. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 101.57, the valuation of EAPI can be described as expensive.
Based on the Price/Forward Earnings ratio, EAPI is valued a bit more expensive than the industry average as 69.09% of the companies are valued more cheaply.
The average S&P500 Price/Forward Earnings ratio is at 36.12. EAPI is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 101.57 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EAPI indicates a rather cheap valuation: EAPI is cheaper than 98.18% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 4.45 |
4.3 Compensation for Growth
EAPI's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
EAPI's earnings are expected to grow with 37.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.63%
EPS Next 3Y37.28%
5. Dividend
5.1 Amount
No dividends for EAPI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:EAPI (11/27/2025, 5:27:56 PM)
3.108
-0.02 (-0.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners40.65%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap297.09M
Revenue(TTM)882.80M
Net Income(TTM)-124.30M
Analysts46.15
Price Target2.86 (-7.98%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)22.64%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 101.57 | ||
| P/S | 0.34 | ||
| P/FCF | N/A | ||
| P/OCF | 4.25 | ||
| P/B | 0.31 | ||
| P/tB | 0.32 | ||
| EV/EBITDA | 4.45 |
EPS(TTM)-1.31
EYN/A
EPS(NY)0.03
Fwd EY0.98%
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.73
OCFY23.53%
SpS9.24
BVpS9.97
TBVpS9.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.62% | ||
| ROE | -13.04% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 13.71% | ||
| FCFM | N/A |
ROA(3y)-7.13%
ROA(5y)-4.46%
ROE(3y)-11.69%
ROE(5y)-7.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.23%
GM growth 5Y10.12%
F-Score5
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.09 | ||
| Cap/Depr | 109.03% | ||
| Cap/Sales | 9.57% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 117.28% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.53 | ||
| Quick Ratio | 0.8 | ||
| Altman-Z | 1.99 |
F-Score5
WACC7.89%
ROIC/WACCN/A
Cap/Depr(3y)120.54%
Cap/Depr(5y)120.13%
Cap/Sales(3y)13.95%
Cap/Sales(5y)12.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.35%
EPS Next Y71.33%
EPS Next 2Y43.63%
EPS Next 3Y37.28%
EPS Next 5Y24.98%
Revenue 1Y (TTM)-9.11%
Revenue growth 3Y0.98%
Revenue growth 5Y0.07%
Sales Q2Q%-8.07%
Revenue Next Year-2.9%
Revenue Next 2Y-3.71%
Revenue Next 3Y-1.19%
Revenue Next 5Y0.98%
EBIT growth 1Y-516.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year260%
EBIT Next 3Y66.31%
EBIT Next 5Y39.37%
FCF growth 1Y90.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2696%
OCF growth 3Y19.68%
OCF growth 5Y28.63%
EUROAPI SASU / EAPI.PA FAQ
Can you provide the ChartMill fundamental rating for EUROAPI SASU?
ChartMill assigns a fundamental rating of 3 / 10 to EAPI.PA.
Can you provide the valuation status for EUROAPI SASU?
ChartMill assigns a valuation rating of 2 / 10 to EUROAPI SASU (EAPI.PA). This can be considered as Overvalued.
How profitable is EUROAPI SASU (EAPI.PA) stock?
EUROAPI SASU (EAPI.PA) has a profitability rating of 2 / 10.
What is the financial health of EUROAPI SASU (EAPI.PA) stock?
The financial health rating of EUROAPI SASU (EAPI.PA) is 4 / 10.
Can you provide the expected EPS growth for EAPI stock?
The Earnings per Share (EPS) of EUROAPI SASU (EAPI.PA) is expected to grow by 71.33% in the next year.